Association of multiple mutations in NS5A and NS5B genes and resistance to direct-acting antivirals in chronically infected Egyptian patients with Hepatitis C virus Genotype 4a
Approximately 71 million people worldwide are supposed to have chronic hepatitis C virus (CHCV). New direct-acting antiviral (DAA) medications have been used, which helped successfully in complete treatment of CHCV and achieved a sustained virological response (SVR). However, some patients may ac...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
ResearchersLinks, Ltd
2024-02-01
|
| Series: | Novel Research in Microbiology Journal |
| Subjects: | |
| Online Access: | https://nrmj.journals.ekb.eg/article_342339_5e2195c25354cef7e25620760655e259.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Approximately 71 million people worldwide are supposed to have chronic hepatitis C
virus (CHCV). New direct-acting antiviral (DAA) medications have been used, which helped
successfully in complete treatment of CHCV and achieved a sustained virological response
(SVR). However, some patients may acquire HCV resistance to DAAs, which may result in
treatments failure. The aim of the present study was to compare among the patients that were
experiencing virologic relapse (VR) and SVR in relation to the patterns of NS5A and NS5B
genes resistance associated substitutions (RASs) in the chronic HCV infected Egyptian
patients, who received Sofosbuvir (SOF) and Daclatasvir (DCV) combination therapy. All
patients that were infected by chronic HCV had completed treatment with SOF and DCV
combination therapy and were followed up after the end of this treatment. A total of 10 out of
100 serum specimens were collected from the enrolled patients and analyzed, where two and
eight specimens were representatives for VR and SVR, respectively. These samples had
undergone reverse transcriptase-polymerase chain reaction amplification (RT-PCR) of NS5A
and NS5B genes, partially sequenced by the Sanger method, and then analyzed
phylogenetically to determine their genetic subtypes and RASs. Finally, SVR was gained in all
but two patients who were experiencing VR that carried natural NS5A-RASs at positions
L31M and Y93H. They were considered as significant for DCV resistance as well as natural
NS5B-RASs (T282S), which represented the main polymorphism for SOF resistance. In this
study, a number of mutational combinations in the analyzed NS5A and NS5B genes were
identified, which may increase the risk of treatments failure in the patients administered
regimens including multiple DAA, compared to the baseline sequences of those patients that
were experiencing SVR. |
|---|---|
| ISSN: | 2537-0286 2537-0294 |